Acute myeloid leukaemia (supportive care)
Also known as: Acute myeloid leukemia, AML, Acute myelogenous leukaemia, Acute myeloblastic leukaemia
Acute myeloid leukaemia (AML) is a serious malignancy of myeloid blood-forming cells that requires specialist haematology management. Care depends on disease biology, molecular risk, fitness, and treatment goals, often involving antileukaemic medicines, transplantation, and clinical trials. Supportive care is used to manage infection, haemorrhage, fatigue, nutrition, and treatment side effects. While a TCM assessment may offer a framework for discussing symptoms, it must never delay medical investigation or interfere with oncology care. The evidence cited here outlines advances in AML management but does not evaluate acupuncture or Chinese herbal medicine; therefore, no AML-specific benefits have been established. Any proposed intervention requires agreement from the haematology team, a review of current blood counts, and medication reconciliation, especially during intensive treatment.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere strictly to infection control protocols, food-safety guidelines, and immunisation schedules as directed by the haematology service; complementary care is not a substitute for these clinical measures.
- •Perform gentle, paced physical activity once medically cleared, modifying intensity based on current levels of fatigue, dizziness, and haemorrhagic risk.
- •Maintain a systematic record of body temperature (as clinically indicated), nutritional intake, hydration status, and any symptomatic changes or haemorrhagic events for specialist review.
- •Prioritise sleep hygiene and consistent dietary patterns; utilise dietetic and psycho-oncological services rather than unverified supplements.
Cautions & Contraindications
- •Defer acupuncture during suspected infection, febrile neutropenia, active bleeding, clinically significant thrombocytopenia or coagulopathy, or medical instability. Obtain current blood counts and explicit treating-team agreement; use local oncology thresholds rather than a universal cut-off. This is a safety precaution, not a conclusion tested in the supplied review.[]
- •Do not needle infected skin, mucositis, bruises, tumours, wounds, catheter or port sites, or limbs subject to local procedural restrictions. Avoid vigorous needling, bleeding techniques, cupping and gua sha where bleeding or skin injury is a concern.[]
- •Do not start a listed formula without full product and ingredient review by the haematologist and oncology pharmacist. Compatibility with chemotherapy, targeted medicines, antifungals, anticoagulants and transplant immunosuppression cannot be assumed; this review provides no herbal-interaction evidence.[]
- •Pregnancy, organ dysfunction and the transplant period require additional specialist assessment. Avoid herbal prescribing when interaction or product-quality uncertainty cannot be resolved, and never use TCM pattern findings to reduce or delay prescribed treatment.[]
When to reassess or seek care again
Before every proposed session, check current treatment phase, oncology instructions, clinically relevant blood counts, infection symptoms, bleeding and medication changes. If adjunctive care is approved, review within 7 days using 0–10 fatigue and nausea ratings, sleep duration, oral intake, weight trend and adverse effects. Stop and refer promptly for deterioration; reassess the plan after 2–3 sessions if no meaningful symptom improvement occurs. Blood-count recovery, remission and survival must not be attributed to TCM care.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Lancet (London, England) · 2018
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
